Medibiofarma obtiene un millón de euros para impulsar la Fase Clínica de sus tres fármacos

by Medibiofarma

16 days ago
Medibiofarma, Sodena, Inveready

Medibiofarma, empresa biofarmacéutica navarra que se dedica a descubrir y desarrollar nuevas terapias para enfermedades de alta necesidad médica, ha cerrado una ronda de financiación por valor de u...

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer

by Ability Pharma

1 month ago
AbilityPharma, ABTL0812, CTI Life Sciences Fund, Inveready, EIC Fund

AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...

Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team

by Palobiofarma

2 months ago
Palobiofarma, Sodena, Inveready

The investment will be used to complete three phase II clinical trials in which the efficacy of its most advanced products is being studied, namely PBF-680 in patients with chronic obstructive pulmona...

MiMARK Diagnostics, S.L. successfully Closes First Seed Round with €4.22 Million to Impact on Gynecological Diagnostics

by MiMARK Diagnostics

5 months ago
Canterbury Scientific, MiMARK Diagnostics, EIC Accelerator, Clave Capital, Nara Capital, Namarel Ventures, WA4STEAM, CDTI Innvierte, Inveready

MiMARK Diagnostics, S.L. a pioneering femtech spin-off from the Vall d'Hebron Research Institute (VHIR), has successfully raised €4.22 million as seed round stage. The substantial investment will dr...

Nace StereoDive Medical SL, spin-off de Galgo Medical, con el apoyo de Inveready

by StereoDive

5 months ago
Stereodive Medical, Inveready

Stereodive Medical es una empresa que nace con una sólida experiencia en el desarrollo de soluciones de software de post-procesado de imágenes. Creemos que aporta un producto innovador, StereoDiver,...

We interview Sara Secall, Inveready’s Director of Investments in Life Sciences

by GENESIS Biomed

3 years ago
Life Sciences, Inveready, Sara Secall, drugs, diagnosis, Health, gene therapy

Sara Secall, a chemistry graduate with a master’s degree in environmental science and an MBA, is the current partner and director of investments in Life Sciences at Inveready, a Venture Capital (VC)...

Connecta Therapeutics raises €1.7 M in a round led by Inveready to develop new treatment for fragile X syndrome

by Inveready

4 years ago
Inveready, Prous Institute for Biomedical Research, CDTI, Connecta Therapeutics, FXS, neuroplasticity, autism, Rett syndrome, Down syndrome

Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...

The biotech company, Oxolife, raises 5 million euros for its Phase II Clinical Trial

by Oxolife

4 years ago
Oxolife, Inveready, CDTI, BStartup, Capital Cell, Clinical Trial, female fertility

The biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer

by Ability Pharma

4 years ago
Inveready, Everis, Sodena, Ability Pharma, BEI, drug, financing, PancreaticCancer

The biopharmaceutical company Ability Pharmaceuticals SL announced today that it has been awarded €5 million blended financing from the Horizon Europe, European Innovation Council (EIC) Accelerator ...

XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma

by Palobiofarma

5 years ago
Novartis, Inveready, tumor, inhibitor, adenosine

XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the asse...

Oncostellae aumenta su capital para financiar el desarrollo preclínico y clínico de sus candidatos a fármacos

by Inveready

7 years ago
Oncostellae, OST-122, Inveready, XesGalicia, Unirisco, RCD – Rousaud Costas Duran

El importe de la ronda asciende a 1,85 millones de euros, destinados a los proyectos de I&D en curso sobre Enfermedad Inflamatoria Intestinal, psoriasis, enfermedades autoinmunes y tumores sólidos. L...

Inyección de 4,78 millones de € para AB-Biotics

by AB-BIOTICS

8 years ago
Seed Capita, MAB Capital, AB-Biotics, Inveready

Con una capitalización bursátil de 16 millones de euros, AB-Biotics buscaba la inyección de recursos para sostener su crecimiento. La empresa de Sant Cugat del Vallès está inmersa en un “exhaus...